Health Care [ 3/12 ] | Health Care Equipment & Supplies [ 22/74 ]
NASDAQ | Common Stock
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.
The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons.
Axogen, Inc. is headquartered in Alachua, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | 0.07 Increased by +600.00% | 0.01 Increased by +600.00% |
| Aug 8, 24 | 0.05 Increased by +266.67% | -0.04 Increased by +225.00% |
| May 2, 24 | -0.06 Increased by +40.00% | -0.07 Increased by +14.29% |
| Mar 5, 24 | -0.06 Decreased by -100.00% | -0.10 Increased by +40.00% |
| Nov 7, 23 | 0.01 Increased by +200.00% | -0.06 Increased by +116.67% |
| Aug 7, 23 | -0.03 Increased by +50.00% | -0.13 Increased by +76.92% |
| May 9, 23 | -0.10 Increased by +50.00% | -0.14 Increased by +28.57% |
| Mar 14, 23 | -0.03 Increased by +62.50% | -0.11 Increased by +72.73% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 48.64 M Increased by +17.86% | -1.86 M Increased by +54.56% | Decreased by -3.82% Increased by +61.45% |
| Jun 30, 24 | 47.91 M Increased by +25.57% | -1.92 M Increased by +71.16% | Decreased by -4.01% Increased by +77.03% |
| Mar 31, 24 | 41.38 M Increased by +12.86% | -6.63 M Increased by +1.12% | Decreased by -16.04% Increased by +12.38% |
| Dec 31, 23 | 42.92 M Increased by +18.69% | -3.89 M Increased by +24.10% | Decreased by -9.07% Increased by +36.05% |
| Sep 30, 23 | 41.27 M Increased by +11.67% | -4.09 M Decreased by -11.63% | Decreased by -9.91% Increased by +0.03% |
| Jun 30, 23 | 38.16 M Increased by +10.74% | -6.66 M Increased by +8.44% | Decreased by -17.46% Increased by +17.32% |
| Mar 31, 23 | 36.66 M Increased by +18.24% | -6.71 M Increased by +40.46% | Decreased by -18.30% Increased by +49.64% |
| Dec 31, 22 | 36.16 M Increased by +14.67% | -5.13 M Increased by +2.97% | Decreased by -14.18% Increased by +15.38% |